Alteplase in acute ischemic stroke: Putting the guidelines into practice

Nandakumar Nagaraja, Harold P. Adams

Research output: Contribution to journalReview articlepeer-review

Abstract

Intravenous recombinant tissue plasminogen activator (rt-PA or alteplase) is the only approved medical intervention for treatment of acute ischemic stroke within the first hours of symptom onset. In this article, we review the preliminary studies of rt-PA in acute ischemic stroke that led to US FDA approval of its use within 3 h of symptom onset. The studies on rt-PA for use beyond 3 h of symptom onset and future reperfusion therapies are discussed. Overviews of the clinical presentation and treatment of acute ischemic stroke and stroke systems of care are described.

Original languageEnglish (US)
Pages (from-to)1035-1045
Number of pages11
JournalCNS Drugs
Volume28
Issue number11
DOIs
StatePublished - Nov 2014

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Alteplase in acute ischemic stroke: Putting the guidelines into practice'. Together they form a unique fingerprint.

Cite this